AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update - AEON Biopharma ( AMEX:AEON )
- Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 - - Type 2a meeting with the FDA anticipated in 4Q'25- - Cash runway expected to support operations through FDA meeting and regulatory feedback -
Evolus ( EOLS ) Q2 Revenue Rises 4%
Evolus ( NASDAQ:EOLS ) , a performance beauty company specializing in aesthetic neurotoxins and hyaluronic acid ( HA ) dermal fillers, reported Q2 2025 results on August 5, 2025. The headline news is a material shortfall in both revenue and earnings, with GAAP revenue reached $69.4 million, ...
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Day One Biopharmaceutical ( NASDAQ:DAWN ) , Digital Turbine ( NASDAQ:APPS )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday. Shares of Super Micro Computer, Inc. SMCI fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter financial results and cut its FY26 sales guidance.
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Astera Labs ( NASDAQ:ALAB ) , Digital Turbine ( NASDAQ:APPS )
Shares of Astera Labs, Inc. ALAB rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter guidance above estimates. The company reported a 20% quarter-over-quarter increase in revenue, reaching a record $191.9 ...
Evolus, Inc. ( EOLS ) Reports Q2 Loss, Lags Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -166.67% and -16.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Haemonetics ( HAE ) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Evolus, Inc. ( EOLS ) Q2 Earnings Expected to Decline
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., May 23, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE: AEON ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today reported the grant in May ...
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
IRVINE, Calif., May 19, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE: AEON ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob ...
Evolus, Inc. ( EOLS ) Reports Q1 Loss, Misses Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -80% and 4.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
SNDL Inc. ( SNDL ) Reports Q1 Loss, Misses Revenue Estimates
SNDL INC (SNDL) delivered earnings and revenue surprises of 33.33% and 4.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Evolus, Inc. ( EOLS ) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
IRVINE, Calif., April 25, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE: AEON ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received ...
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - AEON Biopharma ( AMEX:AEON )
IRVINE, Calif., April 25, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) AEON, a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received ...
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., April 21, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE: AEON ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in ...
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - AEON Biopharma ( AMEX:AEON )
IRVINE, Calif., April 21, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) AEON, a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today the appointment of Rob ...
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Bicara Therapeutics ( NASDAQ:BCAX ) , Amkor Tech ( NASDAQ:AMKR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ( "BPD" ) Type 2a meeting with the FDA in the second half of ...
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors.
Evolus, Inc. ( EOLS ) Q4 Earnings and Revenues Lag Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -83.33% and 0.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AEON Biopharma, Inc. Announces Reverse Stock Split
IRVINE, Calif., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( NYSE: AEON ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 ( k ) biosimilar pathway, today announced that the Company's Board of Directors ...
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
Evolus ( EOLS ) Moves 5.5% Higher: Will This Strength Last?
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OrganiGram ( OGI ) Reports Q1 Loss, Lags Revenue Estimates
OrganiGram (OGI) delivered earnings and revenue surprises of -66.67% and 10.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
IRVINE, Calif., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( NYSE: AEON ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 ( k ) biosimilar pathway, today announced that on February 3, 2025, AEON received a ...
Evolus ( EOLS ) Surges 28.3%: Is This an Indication of Further Gains?
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates - Evolus ( NASDAQ:EOLS ) , New Oriental Education ( NYSE:EDU )
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 1% to 43,920.68 while the NASDAQ rose 0.55% to 19,738.47. The S&P 500 also rose, gaining, 0.71% to 6,039.46. Industrials shares surged by 1.8% on Tuesday.
Crude Oil Down 2%; D.R. Horton Earnings Top Views - D.R. Horton ( NYSE:DHI ) , New Oriental Education ( NYSE:EDU )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 450 points on Tuesday. The Dow traded up 1.07% to 43,951.84 while the NASDAQ rose 0.71% to 19,770.38. The S&P 500 also rose, gaining, 0.85% to 6,047.41. Utilities shares surged by 1.6% on Tuesday.
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Archer Aviation ( NYSE:ACHR ) , China Yuchai Intl ( NYSE:CYD )
U.S. stocks were higher, with the Dow Jones index gaining over 300 points on Tuesday. Shares of Charles Schwab Corporation SCHW rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter financial results.
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering - AEON Biopharma ( AMEX:AEON )
IRVINE, Calif., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. AEON ( the "Company" ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 ( k ) biosimilar pathway, today announced the closing of its previously announced firm ...
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
IRVINE, Calif., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( NYSE: AEON ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 ( k ) biosimilar pathway, today announced the closing of its previously announced ...
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
IRVINE, Calif., Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE: AEON ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 ( k ) biosimilar pathway, today announced that it has commenced a public ...
Here's Why Evolus ( EOLS ) Could be Great Choice for a Bottom Fisher
Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a ...
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus ( EOLS )
Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Evolus, Inc. ( EOLS ) Reports Q3 Loss, Misses Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -137.50% and 2.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet ( PODD ) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Evolus, Inc. ( EOLS ) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
IRVINE, Calif., Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE: AEON ) , a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, ...
Evolus, Inc. ( EOLS ) Reports Q2 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -75% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer - InMode ( NASDAQ:INMD )
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return
Evolus ( EOLS ) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
AEON Biopharma Provides Update on Development Pipeline - AEON Biopharma ( AMEX:AEON )
IRVINE, Calif., May 09, 2024 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) AEON, a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update ...
Evolus, Inc. ( EOLS ) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -85.71% and 0.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
Green Thumb Industries Inc. ( GTBIF ) Surges 22.3%: Is This an Indication of Further Gains?
Green Thumb Industries Inc. (GTBIF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
Counterfeit Botox has been found in several states. Here's what consumers should know.
The US Food and Drug Administration is warning that dangerous counterfeit versions of Botox have been identified in multiple states, putting the safety of consumers at risk.
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 30, 2024 ( GLOBE NEWSWIRE ) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. ( NYSE: AEON. AEON.WS ) , please note that in the first paragraph it incorrectly referenced March 29, 2024 as the Redemption Date.
AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 29, 2024 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( NYSE: AEON. AEON.WS ) ( "AEON" or "the Company" ) , a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, ...
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results - AEON Biopharma ( AMEX:AEON )
- Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine - - Topline data from planned interim analysis of ongoing Phase 2 study in chronic migraine are ...
